1/47
Looks like no tags are added yet.
constipation is from
activated mu receptors in the gut, which decrease acetylcholine and peristalsis, and increases muscle tone
constipation is worsened by
ondansetron, amitriptyline, scopolamine
constipation treatment goal
level 4 stool with prophylaxis
bulk forming laxatives
psyllium, methylcellulose
bulk forming laxatives with opioids
will not work; add bulk without helping motility
docusate moa
anionic surfactant mixes water and fat
docusate use
wastes money and doesn’t work
lubiprostone moa
increases Cl and fluid secretion to the GI tract
lubiprostone use
avoid with methadone, which inhibits Cl secretion
osmotic laxatives
PEG/miralax, glycerin
PEG moa
nonabsorbable, acts in colon at 3 days
PEG dose
17 g TID in 8 oz of liquid
glycerin moa
nonabsorbable, acts in rectum at 30 minutes
glycerin suppository
cannot use in neutropenic patients
stimulant laxatives
senna, bisacodyl
senna moa
stimulates intestinal mucosal nerve plexus
senna dose
4 tabs Q12h, works at 8-12 hours
PAMORAs and moa
methylnaltrexone, naloxegel
peripheral mu receptor antagonists (don’t cross BBB)
PAMORAs used when
no bowel obstruction, last line
methylnaltrexone notes
adjust if CrCl < 60, works too fast
naloxegel notes
adjust if CrCl < 60, 3A4 interactions
urinary retention is from
activated mu receptors which reduce bladder contraction
urinary retention is worsened by
active metabolites, epidural administration, cyclobenzaprine, amitriptyline, scopolamine
management of urinary retention
avoid active metabolites, switch to oral, PAMORA
what opioids do not have active metabolites
fentanyl, tapentadol, oxymorphone, methadone
sedation inducing drugs
alprazolam, gabapentin, amitriptyline, scopolamine, alcohol
sedation management
do not drive for 7 days after opioid dose change, or 6 hours after IR dose
sedation treatment
methylphenidate
n/v occurs with
active metabolites after day 5, females, under 50 y/o, constipation
n/v prophylaxis is given if
patient has history; haloperidol or prochlorperazine
n/v treatment
haloperidol or prochlorperazine after 5 days, address constipation
pruritis occurs with
epidural administration, ER, morphine
pruritis moa
central (NT release) and peripheral (mast cell degranulation)
pruritis managment
change route of administration, rotate opioid
pruritis prophylaxis is given if
intrathecal/epidural administration
pruritis treatment
naloxone, naltrexone, nalbuphine, gabapentin, ondansetron
hypotension occurs with
morphine, dehydration, IV push
hypotension management
change administration, fentanyl, fluid bolus
delirium occurs with
active metabolites, elderly, dose increase
delirium treatment
opioid rotation, treat constipation, ketamine
OPIAD occurs with
dose > 100, chronic therapy, intrathecal administration, ER, fentanyl, oxycodone, methadone
OPIAD treatment
reduce dose, check labs, buprenorphine
slow tapering
decrease TDD by less than 10% per month
fast tapering
decrease TDD by 10% per week, and at 30% OG dose do 10% of remaining dose per week
immunosuppression occurs with
ER/LA, high dose, codeine, morphine, methadone, fentanyl
immunosuppression management
reduce dose, treat infection, buprenorphine
hyperalgesia moa
glial cell activation (sub P and glutamate release), NMDA activation (central sensitization), and 3-glucuronides
hyperalgesia treatment
reduce/taper opioid, avoid H3G+M3G, give NMDA antagonist